About: http://data.cimple.eu/news-article/d307643a5ef3d03fff12966091ca2ccdcb28d99f6944e0ee29ae3940     Goto   Sponge   Distinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • Pharma giant AstraZeneca on Saturday said it had resumed a Covid-19 vaccine trial after getting the all-clear from British regulators, following a pause caused by a UK volunteer falling ill. "Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so," the company said in a statement. AstraZeneca announced on Wednesday it had "voluntarily paused" its trial of the vaccine developed alongside Oxford University after the volunteer developed an unexplained illness. An independent committee was drafted in to review safety, in what the company and the World Health Organization described as a routine step. The committee "has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume", AstraZeneca said. AstraZeneca's vaccine candidate is one of nine around the world currently in late-stage Phase 3 human trials. In the United States, the company began enrolling 30,000 volunteers across dozens of sites on August 31, and the inoculation is being tested on smaller groups in Brazil and elsewhere in South America. The AZD1222 vaccine uses a weakened version of a common cold-causing adenovirus engineered to code for the spike protein that the Covid-19 coronavirus uses to invade cells. After vaccination, this protein is produced inside the human body, which primes the immune system to attack the coronavirus if the person is later infected. "AstraZeneca is committed to the safety of trial participants and the highest standards of conduct in clinical trials," Saturday's statement read. "The company will continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic." jit/tgb
schema:headline
  • AstraZeneca resumes Covid-19 vaccine trial after UK green light
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software